MedTrace Logo

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

NCT01109316 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2019-03-27

Study results available
· View outcomes & findings →

Summary

This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion \[CSII\]) compared to insulin aspart over 6 days of pump reservoir in-use. The study will also compare the in-use characteristics of insulin lispro infused at 6 days with insulin lispro infused at 2 days.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Insulin lispro 2 day reservoir in-use

Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.

DRUG

Insulin lispro 6 day reservoir in-use

Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.

DRUG

Insulin aspart 6 day reservoir in-use

Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9am - 5pm Eastern (UTC/GMT - 5hrs, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01109316 on ClinicalTrials.gov